Vitiligo-like lesions occurring in patients receiving anti-programmed cell death-1 therapies

Dousset, L.; Boniface, Katia; Sénéschal, Julien

doi:10.23736/s0392-0488.18.06254-5

Cited by 5 publications

(3 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Until now, these clinical symptoms have been reported only in small cohorts and/or case reports. [5][6][7]18,19,[26][27][28] This study has some limitations. First, as a singlecenter study, it may not reflect the general population of patients in whom vitiligo develops under antiePD-1.…”

Section: Discussionmentioning

confidence: 95%

“…Vitiligo occurring in patients receiving anti–PD-1 therapies follows a generalized pattern with ovalar and/or multiple flecked lesions mainly located on sites of chronic sun exposure, such as the face, neck, neckline, and forearms. 5 , 7 , 18 The link between ultraviolet impregnation and the development of vitiligo in patients with metastatic melanoma treated with anti–PD-1 therapies has recently been investigated. Lo et al 19 found that tumor samples from patients with advanced melanoma who responded well to ICI were enriched for gene sets related to pigmentation, including expression of melanocyte antigens.…”

Section: Discussionmentioning

confidence: 99%

“…Until now, these clinical symptoms have been reported only in small cohorts and/or case reports. 5 , 6 , 7 , 18 , 19 , 26 , 27 , 28 …”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Analysis of tumor response and clinical factors associated with vitiligo in patients receiving anti–programmed cell death-1 therapies for melanoma: A cross-sectional study

Dousset¹,

Pacaud²,

Barnetche

et al. 2021

JAAD International

Self Cite

View full text Add to dashboard Cite

Background: Clinical factors associated with vitiligo in patients receiving antieprogrammed cell death-1 (PD-1) remain unknown.Objective: To better characterize the occurrence of vitiligo in patients receiving antiePD-1. Methods:The present single-center ambispective cohort study included patients with melanoma treated with antiePD-1. Progression-free survival, overall survival, and objective tumor response were compared between patients with and those without vitiligo using Kaplan-Meier curves and the log-rank test. Demographic and clinical factors associated with vitiligo were evaluated using multivariate logistic regression.Results: Of the 457 patients included in the study, vitiligo developed in 85 patients. The clinical presentation of vitiligo consisted of the presence of ovalar and multiple flecked white macules, mainly located on chronic sun-exposed areas. The presence of vitiligo was associated with a significant improvement in overall survival and progression-free survival (P \ .001). A Cox proportional hazards model estimation demonstrated markedly improved survival in patients with vitiligo compared with those without vitiligo (aHR [overall survival], 0.20; 95% CI, 0.12-0.33; P \ .001; and aHR [progression-free survival], 0.33; 95% CI, 0.23-0.47; P \.001). In the multivariate logistic regression analyses, men showed an independent increased risk of the development of vitiligo (odds ratio, 1.66). In contrast, the presence of pulmonary metastases was found to be an independent factor associated with a reduced risk of the development of vitiligo (odds ratio, 0.50).Limitations: Single-center ambispective cohort. Conclusion:Vitiligo in patients receiving antiePD-1 for advanced melanoma is associated with a better outcome. A gender effect associated with the development of vitiligo will need further investigation. ( JAAD Int 2021;5:112-20.)

show abstract

Section: Discussionmentioning

confidence: 95%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Analysis of tumor response and clinical factors associated with vitiligo in patients receiving anti–programmed cell death-1 therapies for melanoma: A cross-sectional study

Dousset¹,

Pacaud²,

Barnetche

et al. 2021

JAAD International

Self Cite

View full text Add to dashboard Cite

show abstract

Middle-Aged Man with Hypopigmented Macules

Trane

Colucci

Moretti

2020

Clinical Cases in Melanoma

View full text Add to dashboard Cite

Cutaneous adverse events in patients treated with PD-1/PD-L1 checkpoint inhibitors and their association with survival: a systematic review and meta-analysis

Zhao

Zhu

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Immune-related cutaneous adverse events (irCAEs) in patients treated with programmed cell death-1/programmed death-ligand 1 (PD-1/PD-L1) checkpoint inhibitors may be associated with better clinical outcomes. However, the extent to which these results can be extrapolated to all tumour types remains unclear. Herein, we conducted a meta-analysis of patients with cancer receiving anti-PD-1/PD-L1 immunotherapy, to determine the cumulative incidence of irCAEs and their association with survival. We systematically searched six databases (PubMed, Embase, Cochrane, CNKI, CSPD, and CQVIP database) for all cohort studies reporting the relationship between irCAEs and patient survival from the time of database construction to 1 November, 2020. The primary outcomes were objective response rate (ORR), progression-free survival (PFS), and overall survival (OS), with complete remission (CR), partial remission (PR), stable disease (SD), and progressive disease (PD) as secondary outcomes. Patients with irCAEs exhibited higher ORR, and were more likely to report CR and PR and less likely to develop PD than those who did not experience irCAEs. Moreover, the occurrence of irCAEs was significantly associated with both favourable PFS and OS. Therefore, patients with irCAEs have better survival benefit and a significantly lower risk of tumour progression or death. Hence, the occurrence of irCAEs may be a useful marker for predicting the clinical efficacy of anti-PD-1/PD-L1 immunotherapy.

show abstract

Vitiligo-like lesions occurring in patients receiving anti-programmed cell death-1 therapies

Cited by 5 publications

References 71 publications

Analysis of tumor response and clinical factors associated with vitiligo in patients receiving anti–programmed cell death-1 therapies for melanoma: A cross-sectional study

Analysis of tumor response and clinical factors associated with vitiligo in patients receiving anti–programmed cell death-1 therapies for melanoma: A cross-sectional study

Middle-Aged Man with Hypopigmented Macules

Cutaneous adverse events in patients treated with PD-1/PD-L1 checkpoint inhibitors and their association with survival: a systematic review and meta-analysis

Contact Info

Product

Resources

About